Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent

Published on 2025-05-27 at 11:10

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about XOMA Royalty Corporation

Essa Pharma Inc. announces definitive agreement to be acquired by Xenotherapeutics, Inc., backed by XOMA Royalty Corporation in all-cash transaction	07-14	RE
Xoma Royalty Agrees to Acquire Turnstone Biologics	06-27	MT
XOMA Royalty Corporation agreed to acquire Turnstone Biologics Corp.	06-26	CI
XOMA Royalty Corporation Approves Amendment to the By-Laws	05-30	CI
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent	05-27	MT
Bioinvent sells royalty and milestone rights for mezagitamab to Xoma Royalty	05-27	FW
Xoma Royalty Buys Mezagitamab Royalty, Milestone Rights Held By Bioinvent For Up To $30 Mln	05-27	RE
Bioinvent sells royalty and milestone rights for mezagitamab to XOMA Royalty for up to $30 million	05-27	FW
Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	05-13	CI
XOMA Royalty Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Benchmark Initiates XOMA Royalty at Buy With $35 Price Target	04-17	MT
Xoma Royalty Sells Pipeline Assets Acquired From Kinnate Biopharma	04-14	MT
Xoma Royalty Completes Sale Of Kinnate Pipeline Assets	04-14	RE
An unknown buyer acquired Kinnate Pipeline Assets of XOMA Royalty Corporation for $270 million.	04-13	CI
Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	03-17	CI
XOMA Royalty Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	03-17	CI
XOMA Royalty Acquires Pulmokine for $20 Million	12-02	MT
XOMA Royalty Corporation acquired Pulmokine, Inc. for $45 million.	12-01	CI
Earnings Flash (XOMA) XOMA CORPORATION Posts Q3 Revenue $7.2M	11-07	MT
Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	11-07	CI
XOMA Royalty Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
XOMA Royalty Acquires Royalty Interest in Twist Bioscience's Biopharma Programs	24-10-22	MT
XOMA Royalty Corporation Acquires 50% of Twist's Existing Royalty and Milestone Economics for $15 Million	24-10-22	CI
Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	24-08-13	CI
XOMA Royalty Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-13	CI